GET DAILY SIGNALSInvesco Nasdaq Biotechnology ETF (IBBQ) Offers Broad Exposure to Biotech and Pharma
Key Takeaways
- IBBQ tracks the Nasdaq Biotechnology Index, offering diversified exposure to U.S.-listed biotechnology and pharmaceutical companies.
- The fund holds roughly 247 securities with an expense ratio of 0.19% and approximately $120 million in assets under management (AUM).
- Top holdings Gilead Sciences, Amgen, and Vertex Pharmaceuticals represent about a quarter of the portfolio, concentrating performance in a handful of large-cap names.
- Sector exposure is split between biotechnology (about 65%) and pharmaceuticals (about 35%), with roughly 94% of assets in the United States.
- The fund has traded in a broad range in recent weeks, gaining roughly 3.5% over the trailing 30 days.
Understanding the IBBQ ETF
The Invesco Nasdaq Biotechnology ETF (IBBQ) is a passively managed exchange-traded fund that seeks to track the investment results of the Nasdaq Biotechnology Index. Launched in June 2021, the fund provides broad exposure to biotechnology and pharmaceutical companies listed on the Nasdaq exchange, using a modified market-capitalization weighting methodology. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
The portfolio holds roughly 247 securities, though the fund remains relatively top-heavy. Its largest positions include Gilead Sciences (GILD), Amgen (AMGN), and Vertex Pharmaceuticals (VRTX), which together account for roughly a quarter of total assets. Other notable holdings include Moderna (MRNA), Regeneron Pharmaceuticals (REGN), Illumina (ILMN), Biogen (BIIB), and Revolution Medicines (RVMD).
Sector allocation is concentrated in healthcare, split between biotechnology (approximately 65%) and pharmaceuticals (approximately 35%), with about 94% of holdings domiciled in the United States. The fund carries a competitive net expense ratio of 0.19%.
The Biotech Landscape Today
Biotechnology and pharmaceuticals sit at the intersection of several durable investment themes, including aging demographics, precision medicine, gene editing, and the application of artificial intelligence to drug discovery. Unlike broad-market sectors, biotech returns are heavily influenced by binary clinical-trial outcomes, Food and Drug Administration (FDA) regulatory decisions, and patent lifecycles, which can produce sharp single-stock moves that filter through to sector ETFs.
The broader macroeconomic backdrop remains relevant to the group. Biotechnology companies with little or no current earnings are especially sensitive to interest-rate expectations, because higher discount rates reduce the present value of distant future cash flows. Inflation trends and monetary-policy signals therefore matter for sentiment across the sector, even for an ETF dominated by more established, profitable large-cap names. Merger and acquisition (M&A) activity also remains a recurring catalyst, as larger pharmaceutical firms look to replenish pipelines through acquisitions of innovative biotech companies.
Performance and Positioning Snapshot
IBBQ has exhibited range-bound, choppy trading in recent weeks. After closing near $36.05 in early September, the fund pulled back before recovering, closing near $35.83 in early November. Over the trailing 30 days, the ETF has added roughly 3.5%, while its mid-August level near $33.91 implies a gain of approximately 5–6% over the trailing three months. From what I see, this comparatively muted move reflects the top-heavy structure of the portfolio.
Because a large share of assets sits in established, profitable large-cap biotechs, the fund has been less volatile than a basket of pure-play clinical-stage developers. Meanwhile, elevated one-year returns across several major holdings have supported the index, even as periodic volatility in names such as Moderna has injected short-term swings into the fund's net asset value (NAV).
Looking Ahead to 2026
Looking ahead, several structural factors are likely to influence IBBQ. Interest-rate expectations and inflation trends will remain central, given biotech's sensitivity to discount rates. FDA regulatory developments, clinical-trial readouts, and the pace of new drug approvals will shape the fundamental outlook for major holdings. M&A activity across the pharmaceutical industry could continue to support valuations, while patent expirations and pipeline productivity will drive individual company performance.
Investors should also monitor capital flows into healthcare ETFs, the competitive positioning of large-cap leaders, and the evolving role of artificial intelligence in drug development. The fund's concentration in a handful of large-cap names means that developments at Gilead, Amgen, and Vertex will continue to have an outsized influence on returns, while its broad base of smaller holdings provides diversification against single-stock setbacks.
AI Tools in Portfolio Analysis
In my own work, I have found Tickeron’s AI-powered platforms useful for scanning sector trends and identifying comparable securities. The AI Screener, for instance, lets users apply technical indicators, fundamentals, and pattern recognition across thousands of names, which can help refine exposure decisions in areas like biotechnology without replacing traditional fundamental review.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
Aroon Indicator for IBBQ shows an upward move is likely
IBBQ's Aroon Indicator triggered a bullish signal on November 06, 2026. Tickeron's A.I.dvisor detected that the AroonUp green line is above 70 while the AroonDown red line is below 30. When the up indicator moves above 70 and the down indicator remains below 30, it is a sign that the stock could be setting up for a bullish move. Traders may want to buy the stock or look to buy calls options. A.I.dvisor looked at 257 similar instances where the Aroon Indicator showed a similar pattern. In 232 of the 257 cases, the stock moved higher in the days that followed. This puts the odds of a move higher at 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 26, 2026. You may want to consider a long position or call options on IBBQ as a result. In 74 of 89 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 83%.
The Moving Average Convergence Divergence (MACD) for IBBQ just turned positive on October 20, 2026. Looking at past instances where IBBQ's MACD turned positive, the stock continued to rise in 41 of 50 cases over the following month. The odds of a continued upward trend are 82%.
IBBQ moved above its 50-day moving average on October 27, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for IBBQ crossed bullishly above the 50-day moving average on October 29, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 12 of 16 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 75%.
Following a +3.57% 3-day Advance, the price is estimated to grow further. Considering data from situations where IBBQ advanced for three days, in 263 of 320 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 58 of 70 cases where IBBQ's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 83%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where IBBQ declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 80%.
IBBQ broke above its upper Bollinger Band on October 20, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Category Health
Advertisement